Multiple myeloma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
KPD Variant #01 | — | R 80 082 | 28d | — | — | ~7 | ~R 560 576 indirect | — |
RVD Variant #07 | — | R 17 832 | 21d | ~43.0 mo | — | ~39 | ~R 415 913 PFS proxy · indirect | 9 |
Pomalidomide and Prednisone Variant #01 | — | R 4 840 | 28d | — | — | ~4 | ~R 19 186 indirect | — |
Pomalidomide monotherapy Variant #01 | — | R 4 782 | 28d | ~2.7 mo | — | ~2 | ~R 9 564 PFS proxy · indirect | 1 |
Bortezomib and Cyclophosphamide Variant #01 | — | R 1 789 | 14d | — | — | ~26 | ~R 46 501 indirect | — |
5 of 5 regimens shown